Clinical Trial

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )

Study acronym: CT1190B
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 17, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-27; most recent amendment 2025-11-13.
Status change: Not Yet Recruiting → Recruiting 2025-07-23
Trial Details
NCT Number NCT07053670
Lead Sponsor Tongji Hospital
Conditions B-Cell Non-Hodgkin Lymphoma
Enrollment 27 participants
Start Date 2025-07-09
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-17